Literature DB >> 3842106

Desferrioxamine in the treatment of aluminum overload.

P Ackrill, J P Day.   

Abstract

Aluminum removal is essential in treating patients with aluminum accumulation. Currently the most effective method is chelation of aluminum with desferrioxamine (DFO). DFO administration has been shown to improve dialysis encephalopathy and dialysis bone disease. The optimum dose of DFO and the mode of administration have yet to be determined. Commonly between 40 and 80 mg/kg is given parenterally once weekly. The very high serum aluminum concentrations which develop do not appear to be toxic. The administration of small doses of DFO with each dialysis may also be advocated. Monitoring of serum aluminum levels and of iron status is advisable during DFO treatment. DFO may also play a role in evaluating tissue aluminum accumulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3842106

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Deferoxamine and aluminum clearance in pediatric hemodialysis patients.

Authors:  M R Ogborn; V C Dorcas; J F Crocker
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

2.  Assessment of the developmental toxicity of deferoxamine in mice.

Authors:  M A Bosque; J L Domingo; J Corbella
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.